Abstract Currently, no immunomodulatory agents have been conclusively shown to benefit severe influenza . The World Health Organization conditionally advises against the use of systemic corticosteroids, macrolides, plasma therapy, mechanistic target of rapamycin inhibitors , and nonsteroidal anti-inflammatory drugs for such patients. High-dose systemic corticosteroids may increase mortality and morbidity in severe influenza ; the potential of low-dose corticosteroids merits further study given survival benefits in patients with severe coronavirus disease 2019 ( COVID-19 ). Passive immunotherapy using convalescent plasma or intravenous immunoglobulin (IVIG) from healthy donors has not proven effective , suggesting that future research should focus on hyperimmune plasma or IVIG from recent infections . An open-label randomized controlled trial (RCT) found that a triple combination of oseltamivir, clarithromycin, and naproxen improved outcomes in severe influenza. One RCT has indica...